ROFI, ELEONORA
 Distribuzione geografica
Continente #
NA - Nord America 1.717
EU - Europa 677
AS - Asia 253
AF - Africa 79
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 8
SA - Sud America 3
Totale 2.746
Nazione #
US - Stati Uniti d'America 1.681
IT - Italia 299
CN - Cina 126
SE - Svezia 122
BG - Bulgaria 78
SG - Singapore 60
CI - Costa d'Avorio 58
DE - Germania 50
GB - Regno Unito 47
CA - Canada 35
VN - Vietnam 31
AT - Austria 30
FR - Francia 13
SN - Senegal 12
NL - Olanda 10
EU - Europa 8
IN - India 8
NG - Nigeria 8
AU - Australia 7
ES - Italia 6
HK - Hong Kong 6
JP - Giappone 6
KR - Corea 6
PL - Polonia 5
BE - Belgio 3
BR - Brasile 3
FI - Finlandia 3
CH - Svizzera 2
LK - Sri Lanka 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
RO - Romania 2
RU - Federazione Russa 2
TR - Turchia 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
HR - Croazia 1
IL - Israele 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
NO - Norvegia 1
UZ - Uzbekistan 1
Totale 2.746
Città #
Fairfield 233
Woodbridge 218
Houston 162
Chandler 139
Ashburn 126
Seattle 110
Cambridge 82
Serra 78
Sofia 78
Wilmington 77
Ann Arbor 72
New York 59
Abidjan 58
Pisa 54
Florence 43
Princeton 42
Beijing 31
Lawrence 31
Ottawa 30
Vienna 29
Frankfurt am Main 25
London 25
Medford 23
Nanjing 19
Dearborn 18
Des Moines 16
Dong Ket 15
Boulder 14
Dakar 12
Chiesina Uzzanese 11
Rome 11
Washington 10
Redwood City 9
San Diego 9
Hefei 8
Lagos 8
Kunming 7
Bremen 6
Hong Kong 6
Iowa City 6
San Francisco 6
Changsha 5
Columbus 5
Guangzhou 5
Phoenix 5
Shanghai 5
Kilburn 4
Milan 4
Chengdu 3
Genoa 3
Hebei 3
Jiaxing 3
Lancaster 3
Nanchang 3
Norwalk 3
Ogden 3
Pistoia 3
Shenyang 3
Warsaw 3
Zhengzhou 3
Amsterdam 2
Baotou 2
Brussels 2
Camaiore 2
Chicago 2
Esslingen am Neckar 2
Kolkata 2
Lucca 2
Montréal 2
Nutley 2
Perth 2
Polska 2
Prato 2
Riga 2
Santiago De Compostela 2
Savona 2
Seoul 2
Tappahannock 2
Tianjin 2
Vicopisano 2
Auckland 1
Azor 1
Bari 1
Bellingham 1
Berlin 1
Bucharest 1
Bukhara 1
Cagliari 1
Caserta 1
Castelnuovo Rangone 1
Colombo 1
Daejeon 1
Dallas 1
Daly City 1
Diemen 1
Diyarbakir 1
Dubai 1
Edinburgh 1
Formigine 1
Freitas 1
Totale 2.145
Nome #
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 233
null 142
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 124
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 117
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 117
Clinical pharmacology of intravitreal anti-VEGF drugs 106
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response 106
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 105
Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. 104
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 104
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer 99
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? 99
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 95
Implications of KRAS mutations in acquired resistance to treatment in NSCLC 94
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 92
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 87
Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment 84
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 83
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report 83
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy 77
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 74
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring 71
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 71
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers 63
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 61
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 61
null 60
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7 54
Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells 53
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers 49
Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer 45
Should CYP2D6 be genotyped when treating with tamoxifen? 29
Should CYP2D6 be genotyped when treating with tamoxifen? [Letter in reply] 14
Totale 2.856
Categoria #
all - tutte 8.340
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.340


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019177 0 0 0 0 0 0 0 0 0 35 74 68
2019/2020681 61 71 73 48 66 76 76 70 64 33 33 10
2020/2021238 16 18 7 17 11 12 19 14 42 15 30 37
2021/2022318 3 14 7 7 64 62 16 8 20 11 16 90
2022/2023587 59 85 45 32 49 60 1 40 148 5 61 2
2023/2024287 19 21 71 19 40 78 18 12 8 1 0 0
Totale 2.856